The Office of the U.S. Trade Representatives released its annual report on the adequacy and effectiveness of intellectual-property protection in countries trading with the United States.
The Office of the U.S. Trade Representatives released its annual report on the adequacy and effectiveness of intellectual-property protection in countries trading with the United States.
The 1997 Special 301 Annual Review cited several countries for failing to adequately protect pharmaceutical intellectual property. Five - Argentina, Ecuador, Egypt, India and Turkey - were designated "Priority Watch" countries, and a special review was scheduled to assess Turkey's progress in improving patent protection.
"Without effective intellectual-property protection, there would be no innovative medicines," said Harvey E. Bale Jr., senior vice president of international affairs for Pharmaceutical Research and Manufacturers of America. PhRMA considers patents to be the lifeblood of its industry.
PhRMA asked that the government designate Argentina and India "Priority Foreign Countries" in order to expedite resolution of patent protection problems in those countries. Both are centers of regional and global patent piracy, according to PhRMA.
Other countries put on the "Watch" list for deficiencies related to pharmaceuticals include Australia, Chile, Columbia, Costa Rica, Israel, Jordan, Korea, Kuwait, Oman, Pakistan, Peru and the United Arab Emirates. The review also noted problems in Cyprus, Qatar and Romania.
"This report should prompt countries cited for deficiencies to improve their protection of intellectual property," Bale said.
"This will not only help them meet international standards, it will also benefit the people of those countries by making more innovative medicines available and by attracting investment," according to Bale. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.